A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors

An Investigator-Initiated Study to Evaluate PSMA Expression in Patients With High-Grade Gliomas or Brain Metastases With 68Ga-PSMA-11 PET

The purpose of this study is to find out whether 68Ga-PSMA-11 PET/CT is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/HGG or brain metastases.

Inclusion Criteria:

• Ability to understand and the willingness to sign (or their legally acceptable representative (LAR) must sign) a written informed consent document
• Adults ≥ 18 years old
• Suspicion for or histologically or cytologically confirmed and previously treated HGG or brain metastases from a primary extracranial malignancy
• Lesion size ≥ 1 cm (for the lesion to be biopsied)
• ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
• Planned to undergo biopsy/resection of brain lesion

Exclusion Criteria:

• Inability to undergo a PET scan (e.g., claustrophobia or noncompatible implant in case PET/MR is performed)
• Pregnant or nursing female. All women of childbearing potential must have a documented negative serum or urine pregnancy test <1 week before study.
• Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Patients with severe allergy to both iodinated and gadolinium contrast.